Anne D Talley1, Lauren A Boller2, Kerem N Kalpakci3, Daniel A Shimko3, David L Cochran4, Scott A Guelcher1,2,5. 1. Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee. 2. Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee. 3. Medtronic Spinal & Biologics, Memphis, Tennessee. 4. Department of Periodontics, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 5. Center for Bone Biology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
OBJECTIVE: The objective of this study was to test the hypothesis that a compression-resistant bone graft augmented with recombinant human morphogenetic protein-2 (rhBMP-2) will promote lateral ridge augmentation without the use of protective mesh in a canine model. MATERIALS & METHODS: Compression-resistant (CR) bone grafts were evaluated in a canine model of lateral ridge augmentation. Bilateral, right trapezoidal prism-shaped defects (13-14 mm long × 8-9 mm wide × 3-4 mm deep at the base) in 13 hounds (two defects per hound) were treated with one of four groups: (i) absorbable collagen sponge + 400 μg rhBMP-2/ml (ACS, clinical control) protected by titanium mesh, (ii) CR without rhBMP-2 (CR, negative control), (iii) CR + 200 μg rhBMP-2 (CR-L), or (iv) CR + 400 μg rhBMP-2 (CR-H). All animals were euthanized after 16 weeks. Ridge height and width and new bone formation were assessed by μCT, histology, and histomorphometry. The release kinetics of rhBMP-2 from CR bone grafts in vitro and in vivo in a femoral condyle defect model in rabbits was also evaluated. RESULTS: All four bone grafts promoted new bone formation (11-31.6 volume%) in the lateral ridge defects. For CR grafts, ridge height and width increased in a dose-responsive manner with increasing rhBMP-2 concentration. Ridge height and width measured for CR-H without the use of protective mesh was comparable to that measured for ACS with a protective mesh. CONCLUSIONS: At the same dose of rhBMP-2, an injectable, compression-resistant bone graft resulted in a comparable volume of new bone formation with the clinical control (ACS). These findings highlight the potential of compression-resistant bone grafts without the use of protective mesh for lateral ridge augmentation.
OBJECTIVE: The objective of this study was to test the hypothesis that a compression-resistant bone graft augmented with recombinant human morphogenetic protein-2 (rhBMP-2) will promote lateral ridge augmentation without the use of protective mesh in a canine model. MATERIALS & METHODS: Compression-resistant (CR) bone grafts were evaluated in a canine model of lateral ridge augmentation. Bilateral, right trapezoidal prism-shaped defects (13-14 mm long × 8-9 mm wide × 3-4 mm deep at the base) in 13 hounds (two defects per hound) were treated with one of four groups: (i) absorbable collagen sponge + 400 μg rhBMP-2/ml (ACS, clinical control) protected by titanium mesh, (ii) CR without rhBMP-2 (CR, negative control), (iii) CR + 200 μg rhBMP-2 (CR-L), or (iv) CR + 400 μg rhBMP-2 (CR-H). All animals were euthanized after 16 weeks. Ridge height and width and new bone formation were assessed by μCT, histology, and histomorphometry. The release kinetics of rhBMP-2 from CR bone grafts in vitro and in vivo in a femoral condyle defect model in rabbits was also evaluated. RESULTS: All four bone grafts promoted new bone formation (11-31.6 volume%) in the lateral ridge defects. For CR grafts, ridge height and width increased in a dose-responsive manner with increasing rhBMP-2 concentration. Ridge height and width measured for CR-H without the use of protective mesh was comparable to that measured for ACS with a protective mesh. CONCLUSIONS: At the same dose of rhBMP-2, an injectable, compression-resistant bone graft resulted in a comparable volume of new bone formation with the clinical control (ACS). These findings highlight the potential of compression-resistant bone grafts without the use of protective mesh for lateral ridge augmentation.
Authors: Andrea E Hafeman; Katarzyna J Zienkiewicz; Angela L Zachman; Hak-Joon Sung; Lillian B Nanney; Jeffrey M Davidson; Scott A Guelcher Journal: Biomaterials Date: 2010-09-22 Impact factor: 12.479
Authors: Giuseppe Polimeni; Ulf M E Wikesjö; Cristiano Susin; Mohammed Qahash; Richard H Shanaman; Hari S Prasad; Michael D Rohrer; Jan Hall Journal: J Clin Periodontol Date: 2010-05-25 Impact factor: 8.728
Authors: Scott A Guelcher; Vishal Patel; Katie M Gallagher; Susan Connolly; Jonathan E Didier; John S Doctor; Jeffrey O Hollinger Journal: Tissue Eng Date: 2006-05
Authors: Yash M Kolambkar; Joel D Boerckel; Kenneth M Dupont; Mehmet Bajin; Nathaniel Huebsch; David J Mooney; Dietmar W Hutmacher; Robert E Guldberg Journal: Bone Date: 2011-05-18 Impact factor: 4.398
Authors: Jerald E Dumas; Edna M Prieto; Katarzyna J Zienkiewicz; Teja Guda; Joseph C Wenke; Jesse Bible; Ginger E Holt; Scott A Guelcher Journal: Tissue Eng Part A Date: 2013-10-02 Impact factor: 3.845
Authors: Mohammed E Grawish; Lamyaa M Grawish; Hala M Grawish; Mahmoud M Grawish; Salwa A El-Negoly Journal: Tissue Eng Regen Med Date: 2020-07-03 Impact factor: 4.169
Authors: Lauren A Boller; Archie A Jones; David L Cochran; Scott A Guelcher Journal: Int J Oral Maxillofac Implants Date: 2020 May/Jun Impact factor: 2.804
Authors: Thomas J Spoonmore; Caleb A Ford; Jacob M Curry; Scott A Guelcher; James E Cassat Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Lauren A Boller; Madison A P McGough; Stefanie M Shiels; Craig L Duvall; Joseph C Wenke; Scott A Guelcher Journal: Materials (Basel) Date: 2021-07-15 Impact factor: 3.623